Vaseghi et al (Circulation 2017;135:2255, PMID 28641796) assessed the outcomes of
cardiac sympathetic denervation (CSD) for refractory ventricular arrhythmias. One
hundred twenty-one patients (age 55 ± 13 years; 26% women; mean ejection fraction
30% ± 13%) underwent left or bilateral CSD. One-year freedom from sustained ventricular
tachycardia/implantable cardioverter-defibrillator (VT/ICD) shock and ICD shock, transplant,
and death were 58% and 50%, respectively. CSD reduced the burden of ICD shocks from
a mean of 18 ± 30 (median 10) in the year before study entry to 2.0 ± 4.3 (median
0) at a median follow-up of 1.1 years (P < .01). Preprocedure New York Heart Association (NYHA) functional class III and IV
heart failure and longer VT cycle lengths were associated with recurrent ICD shocks.
Advanced NYHA functional class, longer VT cycle lengths, and a left-sided–only procedure
predicted the combined end point of sustained VT/ICD shock recurrence, death, and
transplantation. Of the 120 patients taking antiarrhythmic medications before CSD,
39 (32%) no longer required them at follow-up. The authors conclude that CSD decreased sustained VT and ICD shock recurrence in patients
with refractory VT.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Heart RhythmAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Published online: July 18, 2017
